We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 422

Application to vary the ownership of patent granted where assignor inadvertently assigned rights to Gray Automotive Products, Inc., as opposed to Gray Automotive Products Co.
  • Borden Ladner Gervais LLP
  • Canada
  • February 4 2016

The Federal Court granted an application under section 52 of the Patent Act to vary all entries of the Patent Office relating to the ownership of


BC Court of Appeal overturns Class Certification in Patents Case, finding Patent Regime to be Complete Code in respect of Remedies
  • Borden Ladner Gervais LLP
  • Canada
  • January 25 2016

In Low v. Pfizer Canada Inc., a unanimous division of the Court of Appeal for British Columbia restricted the ability of consumers to make claims


Standard of Review of Palpable and Overriding Error Not Applied in Appeal from Rule 51 Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 27 2016

This is an appeal from the Federal Court's (FC) decision (2015 FC 797), which upheld the Prothonotary's decision allowing the generic Respondent's


Statements in a generic’s Product Monograph were not found to amount to an inducement to infringe
  • Borden Ladner Gervais LLP
  • Canada
  • April 13 2015

The Court has allowed a motion to strike portions of an application pursuant to Paragraph 6(5)(b) of the PM(NOC) Regulations. The generic respondent


Import Ban Quashed, and Health Canada Ordered to Retract Its Statements re Same
  • Borden Ladner Gervais LLP
  • Canada
  • January 13 2016

Apotex et al brought a judicial review of the Minister of Health's (the Minister) decision to impose an import ban on products from two of Apotex'


Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a


Pleadings for disgorgement of profits and for an accounting of profits in s.8 damages not struck in Ontario court
  • Borden Ladner Gervais LLP
  • Canada
  • August 1 2012

In this case, Apotex has claimed damages in Ontario Court pursuant to, inter alia, section 8 of the NOC Regulations. Lilly brought a motion to strike out parts of Apotex’ statement of claim


Doctrine of bona fide purchaser for value without notice applies to patent rights
  • Borden Ladner Gervais LLP
  • Canada
  • February 6 2012

This case involves a dispute over who owned certain patent rights


Application for reissue denied
  • Borden Ladner Gervais LLP
  • Canada
  • May 1 2013

The Commissioner concurred with the findings of the Reissue Board and held that the patent did not meet the requirements under subsection 47(1) of the


Court grants prohibition order; finds allegations of obviousness, lack of utility and insufficiency not justified
  • Borden Ladner Gervais LLP
  • Canada
  • January 20 2016

In a decision issued on November 18, 2015, the Federal Court allowed the proceeding, granting Leo Pharma a prohibition order in relation to its